Biogen Appoints Maria Freire as Board Chair Effective June 9 After Dorsa’s Retirement
Biogen’s board elected Dr. Maria C. Freire as chair effective after the June 9, 2026 annual meeting, succeeding Caroline Dorsa who is retiring after 16 years. Freire, on the board since 2021 and serving on governance committees, brings biomedical innovation expertise ahead of lupus and nephrology readouts.
1. Board Chair Transition
Biogen’s Board elected Dr. Maria C. Freire as Chair effective immediately following the June 9, 2026 Annual Meeting, replacing Caroline Dorsa who is retiring after 16 years of service and will not stand for reelection.
2. Freire’s Biomedical Expertise
Dr. Freire joined the board in 2021 and serves on governance committees. She brings extensive experience in biomedical innovation, public–private partnerships and drug development from leadership roles at the National Institutes of Health, the Foundation for the National Institutes of Health, and the Global Alliance for TB Drug Development.
3. Strategic Outlook and Pipeline Catalysts
With Freire at the helm, Biogen enters a catalyst-rich period including potential enabling filings in lupus and nephrology. Her scientific and policy background aligns with the company’s focus on sustainable growth and advancing its renewed pipeline.